Recent Updates
Recently added Catalysts

Genmab A/S

GMAB
Fair ValueBiotech · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$36.05
▼ -0.61 · -1.66%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full GMAB financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $23.6252W HIGH $40.17
Volume
4.30 M
Value Traded
86.16 M
Short % Float
0.84%
+3.74%Week
+9.11%1 Month
+24.31%3 Month
+27.61%6 Month
-31.45%5 Year
+612.35%All Time

Cash Data

Unlock GMAB cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
22.49 B
EPS (TTM)
1.34
P/E Ratio
26.92
Ent. Value
19.77 B
Total Shares
623.53 M
Float Shares
587.08 M
Insiders
1.75%
Institutions
18.63%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 interim results
petosemtamab
first- and second/third-line head and neck cancer
Phase 3BiologicsOncology
Unlock every GMAB catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

GMAB Catalyst Timeline

Dated clinical, regulatory and corporate events for Genmab A/S

Catalyst Timeline

Dated clinical, regulatory & corporate events for Genmab A/S

428Total events
11Upcoming
170Tier-1 (high impact)
2018 to 2029Coverage

Upcoming catalysts 2

T2Product Launch
Subscribe to view catalyst details
Petosemtamab
T1FDA Approval
Subscribe to view catalyst details
Petosemtamab

Event history 50

▲Corporate ApprovalCorporate
Genmab shareholders approve 2026 Board remuneration including restricted stock units
source ↗
●Grant / FundingCorporate
5,300 restricted stock units granted to Genmab Board members
source ↗
▲Topline ReadoutEpcoritamabApprovedClinical Data
Positive topline results from Phase 3 EPCORE DLBCL-2 of epcoritamab plus R-CHOP in newly diagnosed DLBCL
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Primary Endpoint MetEpcoritamabApprovedClinical Data
EPCORE DLBCL-2 met primary endpoint of PFS in IPI 3-5 patients (HR 0.49, p<0.0001)
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Topline ReadoutRina-SClinical Data
Rina-S Phase 2 RAINFOL-01 Part C results in PROC: ORR 45.9%, mDOR 12.1 months, mPFS 9.5 months
platinum-resistant ovarian cancersource ↗
▲Oral PresentationRina-SPresentation
Rina-S RAINFOL-01 Part C data presented in Late-Breaking Oral Session at IGCS Congress 2026
platinum-resistant ovarian cancersource ↗
●Safety Data UpdateRina-SClinical Data
Rina-S RAINFOL-01 Part C safety data: no ocular toxicity, peripheral neuropathy, ILD or stomatitis signals
platinum-resistant ovarian cancersource ↗
●Corporate ApprovalCorporate
Darwin Global Management discloses 5.11% voting rights in Genmab A/S
source ↗
▲Topline ReadoutEpcoritamabApprovedClinical Data
Positive Phase 3 results for epcoritamab plus lenalidomide in DLBCL
relapsed/refractory diffuse large B-cell lymphoma (DLBCL)source ↗
▲Quarterly UpdateDARZALEXApprovedCorporate
DARZALEX Q2 2026 net sales of USD 4,207 million
multiple myelomasource ↗
Unlock the full GMAB catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How GMAB actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-03-27Epkinly (epcoritamab-bysp) PDUFA Date ApprovedPDUFA
Unlock 3 more GMAB historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

C59 / 100
Pipeline Score
$5.7B
Pipeline Value
$14.7B
Commercial Value
Fair Value
Valuation Signal
16
Drugs Scored
0.7x
rNPV / MCap
Top 8%
Mid Cap
(rank 54 of 658)
Percentile Rank
Genmab A/S carries a moderate pipeline score (59/100), with $6.7B risk-adjusted pipeline value, led by Petosemtamab in Left-sided Colorectal Cancer (Phase 3), across $164B in total addressable markets.
Commercial products (revenue basis: latest annual revenue in its 20-F, to Dec 2025) Revenue $3.7B x 4.0 = $14.7B
Showing 1 of 16 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Petosemtamab Monoclonal antibodyNCT07702032Left-sided Colorectal CancerPhase 3 NOT YET_RECRUITING 960Sep 1, 2031
Unlock the GMAB pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every GMAB program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
epcoritamab newly diagnosed diffuse large B-cell lymphomaPhase 32026-10-05statistically significant improvement in progression-free survivalRead MoreGenmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaRead More
Scroll for more · summaries link to the source press release
Unlock every GMAB trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock GMAB insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
John SmithCEOBuy 50,000 150,000 held$45.50 01/10/2026
Unlock the full GMAB insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in GMAB

Fund % of Portfolio Current MV Shares Owned Activity
Paradigm Biocapital Advisors LP 6.8 % (54.5 %) 360.77 M 13.13 M 64.83% ( 5.17 M)
Unlock every fund holding GMAB
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in GMAB
Shares held by hedge funds each quarter, and who bought or sold.

GMAB Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock GMAB option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live GMAB option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock GMAB options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How GMAB ranks across every disease it competes in

Competitive Position is a premium feature
See how GMAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

GMAB News

GMAB
Oct 7, 2026
GMABGeneral
▼ -1.7%today

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members

Genmab A/S held an Extraordinary General Meeting where the Board's proposal for 2026 remuneration was approved. This includes the granting of 5,300 restricted stock units to board members, vesting after three years. Each unit is valued at DKK 2,487.00, aligning board members' interests with shareholders.

Read more →
GMAB
Oct 5, 2026
GMABPhases
▼ -1.7%today

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab and AbbVie have reported positive topline results from their Phase 3 EPCORE DLBCL-2 trial. The trial evaluated the efficacy of epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma patients. Results indicate a statistically significant improvement in progression-free survival compared to R-CHOP alone.

Read more →
GMAB
Oct 3, 2026
GMABPhases
▲ +10.7%on this newsshared move

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab announced positive results from the Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The treatment achieved a 45.9% objective response rate and a median duration of response of 12.1 months. Notably, antitumor activity was consistent across varying levels of folate receptor alpha expression. The findings were presented at the IGCS Congress 2026 in Montreal.

Read more →
GMAB
Oct 2, 2026
GMABGeneral

Major Shareholder Announcement

Genmab A/S announced that Darwin Global Management Limited controls 5.11% of its voting rights as of September 28, 2026. This announcement is in compliance with the Danish Capital Markets Act. Genmab is focused on developing innovative antibody therapies for cancer and other serious diseases, with a robust clinical pipeline.

Read more →
GMAB
Sep 29, 2026
GMABGeneral

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association, which are dated September 24, 2026. The document is available on the company's website, indicating a commitment to transparency and corporate governance. This update may be relevant for stakeholders and investors interested in the company's governance framework.

Read more →
GMAB
Sep 24, 2026
GMABGeneral

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab A/S announced the grant of 13,794 restricted stock units and 13,331 warrants to its employees. The restricted stock units will vest after three years, while the warrants will also have a three-year vesting period. This initiative reflects Genmab's commitment to employee engagement and aligns with its goal of advancing innovative antibody medicines.

Read more →
GMAB
Sep 8, 2026
GMABGeneral

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S will increase its share capital by 28,011 shares due to employee warrant exercises. This capital increase, amounting to approximately DKK 44.3 million, will not involve preemption rights for existing shareholders. The new shares will be listed on Nasdaq Copenhagen and will provide rights to dividends and other benefits.

Read more →
GMAB
Sep 8, 2026
GMABGeneral

Notice to Convene an Extraordinary General Meeting of Genmab A/S

Genmab A/S has announced an Extraordinary General Meeting scheduled for October 7, 2026, in Copenhagen. The meeting aims to engage shareholders and discuss important company matters, including Board remuneration proposals. Shareholders can access meeting materials on Genmab's website, reflecting the company's commitment to transparency and communication.

Read more →
GMAB
Sep 1, 2026
GMABGeneral

Genmab Appoints Rodrigo Fernandez-Baca as General Manager, Italy and Spain

Genmab has appointed Rodrigo Fernandez-Baca as General Manager for Italy and Spain, aiming to expand its commercialization efforts in these key markets. With over 20 years of experience in biotech and pharmaceuticals, particularly in oncology, Rodrigo is expected to drive performance and align local teams to improve patient access to innovative antibody-based medicines. His leadership is seen as crucial for Genmab's growth in Europe.

Read more →
GMAB
Aug 25, 2026
GMABConferences/Events

Genmab to Participate in Upcoming Investor Conferences

Genmab A/S has announced participation in several investor conferences in September 2026, including events hosted by Wells Fargo, Morgan Stanley, and Bank of America. The company aims to engage with investors and share insights into its innovative antibody therapeutics. Webcasts of the presentations will be available on Genmab's website.

Read more →
GMAB
Aug 6, 2026
GMABPhases

Genmab Announces Financial Results for the First Half of 2026

Genmab reported positive Phase 3 results for its drug epcoritamab combined with lenalidomide, targeting patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The results showed statistically significant improvements, indicating a potential advancement in treatment for this patient population. This announcement is part of Genmab's interim report for the first half of 2026.

Read more →
GMAB
Jul 23, 2026
GMABPhases

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie have clarified the primary endpoints of the Phase 3 EPCORE DLBCL-1 trial. This study evaluates the efficacy of epcoritamab, a T-cell engaging bispecific antibody, against standard chemoimmunotherapy options in patients with relapsed/refractory diffuse large B-cell lymphoma. The trial aims to provide insights into the treatment's effectiveness.

Read more →
GMAB
Jul 15, 2026
GMABGeneral

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Genmab A/S reported net sales of DARZALEX (daratumumab) totaling USD 4,207 million for the second quarter of 2026. The sales included USD 2,435 million from the U.S. and USD 1,772 million from other global markets. Genmab earns royalties on these sales under its exclusive license agreement with Johnson & Johnson.

Read more →
GMAB
Jul 6, 2026
GMABFDA Updates

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab has announced that its drug TEPKINLY® (epcoritamab), when used in combination with lenalidomide and rituximab, has been approved by the European Commission. This approval is specifically for the treatment of relapsed or refractory follicular lymphoma. The combination therapy is expected to enhance treatment options for patients suffering from this condition.

Read more →
GMAB
Jun 29, 2026
GMABPhases
▲ +5.6%on this newsshared move

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, showing that the combination of epcoritamab and lenalidomide significantly improves progression-free survival in patients with relapsed/refractory diffuse large B-cell lymphoma. The trial met its primary objective, reducing the risk of disease progression and death by 60%. The company plans to engage regulatory authorities for further advancement.

Read more →
GMAB
Jun 15, 2026
GMABGeneral

Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A S

Genmab A S has announced that Orbis Investment Management Limited controls 4.99% of its share capital and voting rights, as of June 12, 2026. This announcement is in compliance with the Danish Capital Markets Act's reporting requirements. Genmab, known for its commitment to improving cancer treatment through antibody medicines, is also advancing a robust clinical pipeline, including various antibody-based therapeutic formats. The company continues to build on over 25 years of experience in this field.

Read more →

About Genmab A/S

3,119 employees genmab.com
BIOPHARMAWATCH ELITE PLUS
Trade the next GMAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime